Design considerations for nanotherapeutics in oncology
Peer Review Sample Work
A review article returned with a reviewer's margin comments
Although listed alongside case reports, this sample is better described as an annotated manuscript review. It reproduces a review article on the design of nanoparticle drug carriers for cancer and overlays it with reviewer comments placed beside the relevant passages, followed by a structured report that ends in a recommendation. The format shows authors what detailed pre-submission feedback looks like: specific, tied to sections of the text, and aimed at strengthening the paper rather than simply judging it.
It will interest researchers in drug delivery and oncology who are preparing review articles, and anyone who wants to see how an independent reviewer reads a manuscript before a journal does.
The EPR effect as both the rationale and the obstacle
The underlying review addresses a well-recognised paradox. Most clinically approved cancer nanomedicines rely on the enhanced permeability and retention (EPR) effect, the tendency of nanoparticles to leak from abnormal tumour blood vessels and accumulate in tumour tissue. These formulations have improved quality of life mainly by reducing the adverse effects of chemotherapy, yet gains in overall survival have been modest. The authors argue that the abnormal tumour microenvironment that enables EPR also limits penetration, producing uneven drug distribution within the tumour.
The review cites approved liposomal products as examples: Doxil (Caelyx), a PEGylated liposomal doxorubicin of about 100 nm; DaunoXome, a 50 nm liposomal daunorubicin; and Myocet, a non-PEGylated liposomal doxorubicin of 150 to 180 nm. It then describes delivery as a sequence of steps (circulation time, crossing the vessel wall, interstitial transport and, in some cases, uptake by cancer cells).
Diffusivity, release rate and binding affinity in targeted designs
For targeted nanoparticles, the review sets out three competing factors once a particle reaches the tumour interstitium: its interstitial diffusivity (D), the release rate constant of the drug (Krel) and the binding affinity of the particle or released drug to cancer cells. It also covers multifunctional and stimuli-responsive systems that respond to internal triggers such as pH, temperature, enzyme activity or redox state, or to external sources such as a magnetic field, ultrasound, heat or light. A summary table of design guidelines leads to three proposed strategies for improving delivery to solid tumours.
Supporting material includes a clinical editor's note, a graphical abstract showing heterogeneous intratumoral distribution of 90 nm liposomes (reproduced with permission from a 1994 Cancer Research paper), and a schematic of stimulus types. The review's own closing remarks acknowledge that its analysis concentrated on the physical properties of nanoparticles and on passive delivery through the EPR effect, a boundary the reviewer later picks up when asking for fuller coverage of stimuli-responsive designs.
What the reviewer flagged, section by section
The inline comments are short and actionable. The reviewer suggests the title could signal its focus more precisely by mentioning nanoparticle design, that the abstract would benefit from naming the specific design parameters and key findings, that the design parameter section needs more detailed explanation or examples, and that the targeting discussion would be stronger with more recent studies.
The closing report is organised under clear headings:
- Strengths: a detailed overview of approved nanoparticles and a well-structured discussion of design parameters.
- Areas for improvement: fuller treatment of stimuli-responsive nanoparticles and recent advances in delivery systems and imaging agents.
- Additional comments: the graphical abstract is effective, while the closing remarks could address future directions.
- Recommendation: accept pending minor revisions.
Using structured feedback before journal submission
A review of this kind helps authors anticipate the comments a journal's referees are likely to raise and address them while changes are still inexpensive. Pubrica's pre-submission peer review follows a similar pattern of inline comments plus a summary report. When a manuscript has already been reviewed by a journal, the same principles apply in reverse: each comment needs a clear, point-by-point reply, which is the focus of Pubrica's support for responding to reviewers.
Authors of narrative reviews in fast-moving fields can take two lessons from this sample. Comments on titles and abstracts are common because these are what editors read first, and requests for recent literature are almost inevitable, so a current literature review and gap analysis before drafting saves revision time. A third lesson concerns reused figures: the graphical abstract here credits its source and notes permission, which journals will check for any image taken from earlier publications.
Questions about this sample
What kind of document is this sample?
It is a review article on nanotherapeutic design in oncology, annotated with a reviewer's inline comments and followed by a structured review report listing strengths, areas for improvement, additional comments and a recommendation to accept pending minor revisions. It illustrates pre-submission manuscript review rather than a clinical case report.
Why does the EPR effect limit as well as enable nanoparticle delivery?
The leaky, abnormal vasculature of tumours allows nanoparticles to accumulate, which is the basis of the EPR effect. The same abnormal microenvironment, however, hinders movement of particles through tumour tissue, so drug distribution is uneven. The review argues that careful particle design is needed to overcome this barrier.
Which approved nanomedicines does the review discuss?
It describes three liposomal products: Doxil (Caelyx), a PEGylated liposomal doxorubicin of about 100 nm; DaunoXome, a 50 nm liposomal daunorubicin; and Myocet, a non-PEGylated liposomal doxorubicin of 150 to 180 nm, along with the cancers for which they were approved.
What changes did the reviewer ask for?
The reviewer suggested a more specific title, an abstract naming the key design parameters, more detail and examples in the design parameter section, recent studies in the targeting discussion, fuller coverage of stimuli-responsive nanoparticles, and closing remarks that discuss future directions in nanotherapeutics for oncology.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
